NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Atossa Therapeutics, Inc. (ATOS) Stock Analysis

Atossa Therapeutics, Inc. (ATOS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ATOS

$2.53

−$0.01 (−0.39%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATOS with… →

ATOS Key Statistics

As of Oct 21, 2026
Trading
Open
$2.53
Previous Close
$2.54
Day's Range
2.39–2.59
52-Week Range
1.70–14.85
Volume
189.56K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.28
Valuation
Market Cap
$25.25M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.45
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$34.77M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.98M
1-Year Return
−82.43%
Dividend and dates
Avg Volume
67.34K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ATOS closed at $2.53, −82.43% over 1 year.

Atossa Therapeutics, Inc. (ATOS) has a market capitalization of $25.25M.

In fiscal 2025, ATOS reported revenue of $0.00.

ATOS Stock Return by Calendar Year

Atossa Therapeutics, Inc. (ATOS) 10-year return: what $10,000 became

1 year
$10,000 $1,757
−82.43%
5 years
$10,000 $596
−94.04%
10 years
$10,000 $78
−99.22%

If you had invested $10,000 in Atossa Therapeutics, Inc. (ATOS) 10 years ago, at the close on October 21, 2016, it would have been worth $78 at the close on October 21, 2026: −99.22% in total, −38.45% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.41%
2025−37.23%
2024+6.82%
2023+66.04%
2022−66.88%
2021+68.42%
2020−39.49%
2019+53.92%
2018−67.31%
2017−81.56%
2016 (partial year)−65.19%

As of October 21, 2026.

ATOS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$34.77M—
2024$0.00−$25.50M—
2023$0.00−$30.09M—
2022$0.00−$26.96M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$37.14M−$34.77M—
2024$0.00—−$27.62M−$25.50M—
2023$0.00—−$31.38M−$30.09M—
2022$0.00—−$27.69M−$26.96M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Atossa Therapeutics, Inc. (ATOS) carries a market capitalisation of $25.25M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 16 employees.

The most recent close on file for ATOS is $2.53, dated October 21, 2026. That is −$0.01 (−0.39%) against the previous close. Over the past 52 weeks the price has ranged from $1.70 to $14.85. The latest close sits 48.82% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $34.77M. Trailing earnings per share are −4.45.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.28. Annualized volatility over the trailing 10 years is 155.91%. Over the trailing twelve months the total return is −82.43%. Measured over 10 years, that is −38.45% a year compounded.

Growth & Income

No dividend is on file for ATOS.

The strongest complete calendar year on file is 2021 at +68.42%; the weakest is 2017 at −81.56%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is −71.41% year to date.

Peer Comparison

Atossa Therapeutics, Inc. (ATOS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Atossa Therapeutics, Inc. ATOS $25.25M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Atossa Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Visit website →